Zobrazeno 1 - 10
of 48
pro vyhledávání: '"59"'
Publikováno v:
Clinical Cancer Research. 23:59-59
Background: Betel nuts-related HNSCCs in Taiwan will cause (1) strong inflammation, invasion, and angiogenesis; (2) poor response to chemotherapy, radiation, and epidermal growth factor receptor inhibitors. Methods: HNSCC cell lines (SCC4, SCC9, SCC1
Autor:
Baris Turkbey, Peter A. Pinto, Joanna H. Shih, Maria Merino, Peter L. Choyke, Ravi A. Madan, John R. Bright, Stephanie Harmon, Guinevere Chun, Fatima Karzai, Huihui Ye, Amy Hankin, Scott Wilkinson, Anna Couvillon, Marijo Bilusic, Lisa M. Cordes, Nicolas T. Terrigino, David J. VanderWeele, Rosina T. Lis, William L. Dahut, Nicole V. Carrabba, Stephanie M. Walker, Monique N. Williams, James L. Gulley, Adam G. Sowalsky
Publikováno v:
Clin Cancer Res
Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the pot
Autor:
Pete S. Batra, Peter C. Revenaugh, Samer Al-Khudari, Kerstin M. Stenson, Hannah N. Kuhar, Ashley Heilingoetter
Publikováno v:
Clinical Cancer Research. 26:B36-B36
Introduction: Elective “prophylactic” tracheostomy has routinely been performed intraoperatively at the time of resection and reconstruction of defects of the head and neck for airway protection in anticipation of potential airway complications.
Autor:
Amit Kumar, Alexander Polo, George A. Dominguez, John Roop, Dmitry I. Gabrilovich, Anthony Campisi
Publikováno v:
Clinical Cancer Research. 26:B50-B50
Prostate cancer (PCa) screening and detection relies heavily upon prostate-specific antigen (PSA) testing, but PSA testing has a high rate of false positives, leading to increased risks for overdiagnosis and overtreatment; thus, additional blood-base
Autor:
Xin Gao, Li Ling, Xian Zhong Bai, Fang Jian Zhou, Ke Ji Xie, Jian Guang Qiu, Xing Qiao Wen, Hao Zhang, Qi Peng Sun, Ming Kun Chen, Ming Yang, Chun Kui Shao, Xiang Fu Zhou, Jun Pang, Zu Lan Su, Zhong Chen, Liao Yuan Li
Publikováno v:
Clinical Cancer Research. 18:4163-4172
Purpose: We aimed to analyze whether ERG rearrangement in biopsies could be used to assess subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia (HGPIN) and the risk of lymph node metastasis in early prostate cancer. Experimen
Publikováno v:
Clinical Cancer Research. 23:15-15
Background: Definitive concomitant chemoradiotherapy (CRT) with high-dose cis-platinum (CDDP) is a current standard protocol for advanced laryngeal and hypopharyngeal cancer sparing surgery for salvage. However, this modality is associated with limit
Publikováno v:
Clinical Cancer Research. 27:5004-5011
Purpose: Statin use is reportedly associated with the risk of prostate cancer, outcomes after treatment, and prostate cancer-specific mortality. We sought to determine the efficacy of adjuvant atorvastatin in prostate cancer after radical prostatecto
Autor:
Paul J Bröckelmann, Bastian von Tresckow, Christian Baues, Peter Borchmann, Helen Goergen, Michael Fuchs, Markus Dietlein, Horst Müller, Jasmin Mettler, Andrea Kerkhoff, Ulrich Keller, Andreas Engert, Conrad-Amadeus Voltin, Carsten Kobe, Stephanie Sasse, Lutz van Heek, Karolin Trautmann-Grill, Julia Meissner
Publikováno v:
Clinical Cancer Research. 27:402-407
Purpose: A primary analysis of the ongoing NIVAHL trial demonstrated unexpectedly high interim complete response rates to nivolumab-based first-line treatment in early-stage unfavorable Hodgkin lymphoma. However, biomarkers such as metabolic tumor vo
Autor:
M Melé, Serafin Morales, Noelia Martínez, Jordi Canes, Begoña Bermejo, I Garau, Paolo Nuciforo, Patricia Villagrasa, Maria Jose Echarri, Antonia Perelló, Barbara Adamo, Blanca Gonzalez-Farre, Silvia Vazquez, Tomás Pascual, Xavier Gonzalez, Santiago Escrivá-de-Romaní, Patricia Galván, Sonia Pernas, Eva Ciruelos, Mafalda Oliveira, D. Martinez, Javier Cortes, Laia Paré, Alvaro Montaño, Aleix Prat, Eduardo Martínez, Estela Vega, Luis Manso
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
CLINICAL CANCER RESEARCH
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
CLINICAL CANCER RESEARCH
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Purpose:To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer.Patients and Methods:PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had
Autor:
Shelonitda Rose, Eric H. Rubin, Kathleen N. Moore, Denise Uyar, Amit M. Oza, Maria D P Estevez-Diz, Marcia Hall, Frederik Marmé, Eva-Maria Grischke, Tomoko Freshwater, Naomi Laing, Robert M. Wenham, Michael Tracy, Ji Liu, Diane Provencher, Mark A Lee, Johanne I Weberpals, Jingjun Qiu
Publikováno v:
Clinical Cancer Research. 26:4767-4776
Purpose: Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy, would enhance efficacy versus placebo in TP53-mutated ovarian cancer. Pati